Proton-Pump Inhibitor (No. II)
The Proton-Pump Inhibitor No. II MDL, centralized in the District of New Jersey in 2017 before Judge Claire C. Cecchi, consolidates claims that long-term use of proton-pump inhibitor medications, a widely prescribed class of heartburn and acid-reflux drugs, causes chronic kidney injury, including cases progressing from acute kidney injury to chronic kidney disease. With 11,404 actions coordinated, this is one of the larger active drug dockets in the federal MDL system, reflecting both the drug class's extremely broad use and a substantial claimant population alleging this injury pattern.
What most distinguishes this docket's resolution-risk profile is the strength of general causation itself, a live and central question given that proton-pump inhibitors are used by a very large population for a common condition, and kidney disease has numerous well-established causes unrelated to medication use. That backdrop makes both general-causation expert testimony and individualized specific-causation proof, meaning distinguishing medication-attributable kidney injury from age-related or comorbidity-driven decline, more central to this docket's duration and resolution risk than in dockets built around a more mechanically distinct or rarer injury signature.
Because of that causation profile, summary-judgment practice around general and specific causation is likely to be a more prominent structural feature of this docket's near-term development than bellwether trial scheduling alone, since causation rulings at that stage can meaningfully affect how much of the claim population can proceed at all. For claims that survive causation challenges and don't otherwise settle, remand to the originating district for trial remains the standard procedural backstop.
Criterica Intelligence's platform is built to identify this kind of causation-driven resolution-risk profile specifically, distinguishing it from device-defect or mechanically distinct drug-injury dockets where causation is comparatively less contested.
Proton-pump inhibitors are used by an extremely large population for a common condition, and kidney disease has numerous well-established causes unrelated to medication use, making the causation link itself a genuinely contested, central question.
Device dockets often center on a discrete mechanical failure mode, while this docket turns heavily on epidemiological and individualized causation evidence distinguishing medication-attributable kidney injury from age-related or comorbidity-driven decline.
Summary-judgment practice on general and specific causation, since rulings at that stage can meaningfully affect how much of the claim population is able to proceed at all.
They proceed toward remand to their originating districts for trial, consistent with standard federal multidistrict litigation procedure.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.